23 - 24 JUNE 2011 BURKITT SYMPOSIUM DENIS PARSONS BURKITT IRISH BY BIRTH, TRINITY BY THE GRACE OF GOD — A LIFE CELEBRATED 23 - 24 June 2011 BURKITT SYMPOSIUM

WELCOME

Dear Friends and Colleagues,

I would like to take this opportunity to welcome you to Dublin to celebrate the one hundredth year anniversary of the birth of Denis Parsons Burkitt, one of the great physician scientists of the twentieth century who had a tremendous ability to turn simple clinical observation into major scientific discovery. We are fortunate, not only to be hosting his centenary at the University of Dublin, Trinity College, where he graduated in medicine in 1935, but also as this Symposium is part of the School of Medicine Tercentenary celebrations.

The Symposium will function as an exclusive forum for family and friends of Professor Owen P. Smith, Denis together with international experts to share and compare experiences in Chair of Haematology, Trinity College, Dublin relation to the lymphoma that is named after him. With this in mind, the first day of the conference will mainly focus on Denis, the man, physician scientist and his main legacy, the discovery and early treatment strategies of the commonest in sub-Saharan African children. The second day will focus on recent developments in term of diagnostics, prognostic markers, risk-stratification methodologies and clinical trial outcomes. The molecular pathobiology of Burkitt lymphoma will be addressed by some of the world’s leading experts and true clinical discussion between practicing physicians and researchers on unresolved issues will follow. At the end of the second day participants will have the advantage of discussing and debating the unresolved issues, especially those most relevant in third world countries.

During the Symposium there will be, for the first time, an exhibition of a selection of key artefacts that were pivotal in nailing down the association of lymphoma incidence and geography.

I hope you find the programme exciting, as I do believe it will provide a meaningful platform providing up-to-date information, not only for basic / translational science researchers but also for clinical haemato-oncologists, nurses and students alike.

I look forward to meeting you over the next two days and to celebrate the life of Denis Parsons Burkitt in the beautiful environs of Trinity College.

Professor Owen P. Smith Chair of Haematology, .

Page 1 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM BURKITT SYMPOSIUM

SUPPORT This Symposium has been made possible by the generous support of: TABLE OF CONTENTS

WELCOME 1 SUPPORT & THANK YOU 2 TABLE OF CONTENTS 3 PROGRAMME - Day 1 4 PROGRAMME - Day 2 5 DENIS PARSONS BURKITT 7 GENERAL SYMPOSIUM INFORMATION 10 FEATURED SPEAKERS 14 NOTES 30

THANK YOU

Mrs Olive Burkitt and daughters Judy, Cas and Rachel Trinity Foundation Office

Maurice Ward Group, especially Chris Primrose for the safe delivery of the donation of Dr Burkitt’s papers to Trinity College

Page 2 Page 3 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: PROGRAMME BURKITT SYMPOSIUM: PROGRAMME

PROGRAMME DAY 1 THURSDAY, 23 JUNE, 2011 PROGRAMME DAY 2 FRIDAY, 24 JUNE, 2011

09.00 - 09.30 Registration / Refreshments in the Anatomy Building 08.30 - 9.00 Registration / Refreshments in the Anatomy Building WELCOME AND INTRODUCTION 09.00 - 11.20 SESSION 3: Molecular Insights 09.30 - 10.00 Professor Owen Smith, Chair of Haematology, University of Dublin, Trinity College, Ireland Chair - Professor Finbarr Cotter, London, UK Dr Mary Robinson, Chancellor of the University of Dublin and Former President of Ireland; Prof Dermot Kelleher Vice-Provost of Medical Affairs TCD; Members of Dr Burkitt’s family - 09.00 - 09.40 Is Burkitt lymphoma an infectious disease — a new role for EBV? Mrs Olive Burkitt, Mrs Cas Boddam Whetham, Mrs Judy Howard Professor Georg Bornkamm Institute of Clinical Molecular Biology and Tumour Generics, German Research Centre for Environmental Health, Germany

10.00 - 12.05 SESSION 1: Historical Perspectives (1) 09.40 - 10.20 New insights into the molecular pathogenesis of Burkitt lymphoma Chair - Professor Owen Smith, University of Dublin, Trinity College, Ireland Professor Riccardo Dalla-Favera Institute for Cancer Genetics and H. Irving Comprehensive Cancer Centre, Columbia University, 10.00 - 10.20 Denis Parsons Burkitt — Irish by birth, Trinity by the grace of God New York, USA Professor Owen Smith University of Dublin, Trinity College, Ireland 10.20 - 11:00 Genomic approaches to molecular diagnosis and molecular targets in Burkitt lymphoma/leukaemia Professor Louis Staudt 10.20 - 10.45 Nailing Burkitt lymphoma — time with Denis in Centre for Cancer Research, National Cancer Institute, Maryland, USA Professor Dennis Wright Former Histopathologist at Makerere Medical School, 11.00 - 11.20 Q & A

10.45 - 11.10 Burkitt lymphoma and the discovery of the Epstein-Barr virus 11.20 - 11.40 Refreshments Professor Sir Anthony Epstein, CBE, FRS Nuffield Department of Medicine, University of Oxford, UK 11.40 - 13.15 SESSION 4: Therapeutic Strategies (1) Chair - Professor Ian Hann, Cork, Ireland 11.10 - 11.45 Into and out of Africa — taking over from Denis Burkitt Professor John Ziegler 11.40 - 12.20 Staging and response evaluation of Burkitt lymphoma University of California – San Francisco, USA Professor John Sandlund St Jude Children’s Research Hospital, Tennessee, USA 11.45 - 12.05 Q & A 12.20 - 13.00 Therapeutic developments Burkitt lymphoma/leukaemia since 1956 12.05 - 13.00 Lunch Professor Ross Pinkerton Queensland Children’s Cancer Centre, Brisbane, Australia

13.00 - 13.15 Q & A 13.00 - 14.50 SESSION 2: Historical Perspectives (2) Chair - Professor Owen Smith, Dublin, Ireland 13.15 - 14.00 Lunch

13.00 - 13.25 Living and dealing with Burkitt lymphoma in Tanzania Dr Trish Scanlan The Ocean Road Cancer Institute, Tanzania 14.00 - 15.40 SESSION 5: Therapeutic Strategies (2) Chair - Dr Elizabeth Vandenberghe, Dublin, Ireland 13.25 - 13.50 Burkitt lymphoma in Uganda: An update on disease status Dr Jackson Orem 14.00 - 14.40 Prognostic factors and current treatment strategies and outcome results in children Uganda Cancer Institute, , Uganda and adolescents with Burkitt lymphoma/leukemia Professor Mitchell S Cairo 13.50 - 14.30 Epidemiological insights into the pathogenesis of endemic and non-endemic Burkitt lymphoma Maria Fareri Children’s Hospital at Westchester Medical Center, New York Medical College, New York, USA Professor Ian Magrath International Network for Cancer Treatment and Research, Belgium 14.40 - 15.20 Burkitt lymphoma in adults Professor David Linch 13.30 - 14.50 Q & A University College London, UK

14.50 - 16.00 Refreshments and break 15.20 - 15.40 Q & A

16.00 - 18.00 Organised tours of Trinity College starting in Anatomy Lecture Theatre 15.40 - 16.00 Refreshments

18.00 - 19.30 Wine reception and Burkitt exhibition - The Old Library

Page 4 Page 5 23 - 24 June 2011 BURKITT SYMPOSIUM: PROGRAMME

16.00 - 18.15 SESSION 6: Therapeutic Strategies & Beyond Chair - Professor Ian Magrath, Brussels, Belgium

16.00 - 16.40 Vaccine therapy for lymphomas — are we there yet? Associate Professor Stephen Schuster University of Pennsylvania Medical School, USA

16.40 - 17.10 Infection and cancer: the legacy of Burkitt Dr Joe Harford Director of the Office of International Affairs, National Cancer Institute, Bethesda, MD, USA

17.10 - 17.50 Burkitt lymphoma — is it possible to cure more with less? Round table discussion with Professor Ian Magrath, Professor John Ziegler, Dr Joe Harford and Professor Owen P Smith

17.50 - 18:05 Closing remarks and farewell Professor Owen P Smith

DENIS PARSONS BURKITT 1911 - 1993 IRISH BY BIRTH, TRINITY BY THE GRACE OF GOD — A LIFE CELEBRATED

A GREAT TWENTIETH-CENTURY IRISH DOCTOR

Page 6 Page 9 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM BURKITT SYMPOSIUM

BURKITT A GREAT TWENTIETH-CENTURY IRISH DOCTOR children of their tumours, he was doing it with drug doses so low that they caused none of the expected side effects. Expert pathologists from around the globe soon acknowledged that this was a newly described disease and coined the name ‘Burkitt lymphoma’ to describe this particular type of tumour. The enormity of Burkitt’s contribution can be assessed from the statistic that Burkitt lymphoma accounts for over half of the childhood in Africa. Born near Enniskillen in , Ireland on 28 February, 1911, Denis himself admitted not being a stellar student. In 1929 he applied to Trinity College Dublin to study his father’s profession, engineering, despite a tutor Denis Burkitt is one of the few medical doctors who won world acclaim for two medical discoveries. The first, as writing to his father expressing doubts if Burkitt would be capable of earning a degree. During his first year at Trinity summarised above, was to uncover the causes and pioneer a cure for the cancer known now as Burkitt lymphoma. The he joined Room 40, a small group of undergraduates who met regularly for prayer and Bible study, and committed his second was to confirm the link between many Western diseases and the lack of fibre in the Western diet. life to Jesus Christ. His religious convictions would be a driving force for the rest of his life. Soon after his commitment to Christianity, he felt that God was calling him to devote his life to medicine. He changed his study to medicine and It was naval surgeon Captain T. L. Cleave who first introduced Burkitt to his theory that refined carbohydrates was the graduated with his MB on 5 July, 1935. After graduating from Trinity College Dublin he continued his surgical training source of many chronic diseases in the Western world. After meticulously researching the world wide geographical and obtained Fellowship of the Royal College of Surgeons in Edinburgh in 1938. He went on to write his MD entitled distribution of bowel cancer, he hypothesised that the deficiency of fibre in the Western diet was the major factor ‘Spontaneous rupture of abdominal viscera’ in 1947. responsible for the high prevalence of this disease in affluent societies. Although at first not considered to be notable, his publications on the role of fibre in the diet increasingly became cited over the next ten years. By 1980 his works While serving as a ship’s surgeon in 1938, Burkitt decided he would be a surgeon first and a missionary second and were considered ‘citation classics’ on the subject of bowel cancer. As his publications on Burkitt lymphoma by this hoped to work with the Colonial Service in West Africa. During his five year sojourn as an army surgeon during World time were also considered ‘citation classics’ it is worth mentioning that not many men have achieved this distinction War Two, he married Olive Mary Rogers, a trainee nurse he had met while working as the Resident Surgical Officer at in two entirely unrelated fields of medical research. the Prince of Wales Hospital in Plymouth. Burkitt was the recipient of many prestigious international awards throughout his career. In 1982 he received the Despite having his application to the Colonial Office being turned down on account of his loss of sight in one eye, Bristol-Myers Award jointly with Tony Epstein for the work they had done in discovering and establishing the importance Burkitt passed a medical and enlisted into the Royal Army Medical Corps. He was posted to a military hospital in of the virus that became known as the Epstein-Barr Virus. That same year Burkitt received the Mott General Motors Mombasa. During his 18 months as an army surgeon he travelled a great deal in East Africa learning Swahili in the Award. Denis Burkitt was also made an honorary Fellow of Trinity College, its highest award, for service in medicine process. Towards the end of the war he applied again to the Colonial Office requesting work as a medical officer in and surgery. Denis Burkitt died on 23 March, 1993. His contributions relieved the world of much misery by directly Uganda. This time his application was accepted. providing a cure for Burkitt lymphoma and indirectly by preventing disease through his high-fibre diet. It has been noted that throughout his life he remained modest and humble. When asked to autograph a book, he used to write: In 1957 Burkitt was asked to examine a five year old boy in the paediatric ward who exhibited tumours in his neck and head. A few weeks he saw another child with the same pattern of malignant jaw tumours. The tumours were extremely fast growing and those affected died within weeks. Believing he was witness to a previously undescribed cancer he began to contact a number of hospitals in Africa. ‘Attitudes are more important than abilities In 1961 along with colleagues Edward Williams and Clifford Nelson, Burkitt undertook a 16,000km research travel visiting at least 56 hospitals in East and Southern Africa. Their mission was to study the occurrence and distribution Motives are more important than methods of lymphomas. Much to their delight, they visited some of the places Livingstone had worked a century before them. Character is more important than cleverness With meticulous data collection along the way they soon realised that the lymphoma was correlated with the same temperature and rainfall zones as malaria leading them to initially believe that the lymphoma may have been linked And the heart takes precedence over the head.’ with the distribution of certain insect carriers as malaria. Always one to conduct his research in the most frugal of manners, the entire expedition cost £678.00 according to Burkitt’s biographer Brian Kellock.

Burkitt’s first published his researchin The British Journal of Surgery in 1958. The publication went unnoticed. It was his article, co-written with Greg O’Conor, entitled ‘Malignant tumours in African children: A clinical syndrome’ and published in Cancer in 1961 that would make a mark in the medical world.

While attending a UK lecture, Burkitt met young virologist Doctor, now Sir Tony Epstein. Burkitt sent Epstein some tumour samples and after three years of searching, Epstein’s team demonstrated a virus in the tumour cells. The Photo Credit: http://understandingscience.ucc.ie/pages/sci_denisburkitt.htm Epstein-Barr virus was the first to be shown to be oncogenic in humans. Following this it was noted that the ‘lymphoma belt’ mapped by Burkitt in Africa corresponded to the areas where mosquitoes thrived, i.e., low level high heat and On a personal note, family was always of major importance in Denis Burkitt’s life and we are pleased and honoured water and where malaria was endemic. The malaria caused the suppression of childhood immune systems and this to welcome to the Symposium his wife Olive Burkitt and two of Denis’ daughters, Judy Howard and Cas Boddam allowed the Epstein-Barr virus to stimulate lymphoid cells to undergo malignant transformation. Whetham. His daughter Rachel was unable to attend but sends her regards.

Using creative thinking, Burkitt convinced the pharmaceutical companies to supply chemotherapeutic agents. His References logic was that due to the lack of radiotherapy equipment and that none of his patients had been exposed to x-rays, http://understandingscience.ucc.ie/pages/sci_denisburkitt.htm and relying solely on medication, the drug companies could assess what effect their drugs were truly having on http://www.whonamedit.com/doctor.cfm/2199.html patients. In giving Burkitt their drugs free of charge, he would use them and report on their efficacy. As Burkitt noted, 1985 Kellock, Brian. The Fibre Man. The Life story of Dr Denis Burkitt. Tring: Lion Publishing plc. “Chemotherapy agents were obtained free of charge from the manufacturers who were approached in an attitude of begging, clothed in the appearance of offering opportunities. In western countries it was difficult to assess the effect of chemotherapy because in most patients, radiotherapy had also been used.” Since monitoring patients was so difficult he thought it unwise to work close to the toxic limits of the drugs, Burkitt discovered that not only was he curing the

Page 8 Page 9 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: GENERAL SYMPOSIUM INFORMATION BURKITT SYMPOSIUM: GENERAL SYMPOSIUM INFORMATION

GENERAL All information about the Chair of Haematology Trinity COMPLETION All registration fees and any other conference will be regularly College Dublin, and members of charges must be paid in full in SYMPOSIUM updated on the website: Dr Burkitt’s family namely Denis OF REGISTRATION order to complete your registration INFORMATION http://www.medicine.tcd.ie/ Burkitt’s wife Mrs Olive Burkitt prior to your arrival. tercentenary/news-events/burkitt- and daughters Mrs Cas Doddam symposium.php. Please check the Whetham and Mrs Judy Howard site regularly for updates. in the Anatomy Building Lecture Theatre. SYMPOSIUM The Symposium will be held in the Access can also be gained via The Symposium officially beings at Anatomy Building Lecture Theatre. the Lincoln Place gate and from 09:30 on Thursday, 23 June, 2011 LOCATION There are three main access points there it is a short walk around the with a Welcome by the former Irish that can be used. The main gate Chemistry Building to the Anatomy President and the Chancellor of to the college on College Green or Building. the University of Dublin Dr Mary the entrance from Nassau Street/ Robinson, Professor Dermot Dawson Street will bring you Kelleher, Vice-Provost of Medical on campus where you can walk Affairs and Head of School of through campus, past College Park Medicine, Professor Owen Smith, to the Anatomy Building.

TRAVEL Please make your own travel College. For more information arrangements to Dublin. about this service see http://www. TO DUBLIN aircoach.ie/aircoach.journey. If arriving by air, transportation wizard.php. from the airport to Dublin’s city Allow 30-60 minutes to get to/from centre is best done by Aircoach, the airport/city centre via Aircoach. a bus service to and from both For those wishing to take a taxi, terminals at Dublin Airport. The there is a taxi rank outside the Aircoach makes a stop at Trinity main gates of Trinity College. College, very close to the front gates, and within easy walking distance of several hotels. Round trip cost is approximately 12 euros. The return Aircoach to the airport leaves from Dawson Street or Suffolk Street every ten minutes which is very close to Trinity

ACCOMMODATION Please make your own CONFERENCE The Conference Reception Desk accommodation arrangements. will be located in the Anatomy RECEPTION DESK Building. Upon arriving please There are numerous hotels in the register. You will receive your city centre. We have contacted a Symposium Programme as well few for special rates and they are as a Symposium badge at that noted on our website at: http:// time. Please wear your badge at www.medicine.tcd.ie/tercentenary/ all times during the Symposium news-events/burkitt-symposium. as only delegates with official php#accommodation. Please Symposium ID will be allowed into note that a few hotels only offer any of the sessions and functions. the rates if booked prior to noted dates.

Page 10 Page 11 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: GENERAL SYMPOSIUM INFORMATION BURKITT SYMPOSIUM: GENERAL SYMPOSIUM INFORMATION

SESSIONS & Sessions Papers CATERING & DINNERS Refreshments will be served If you have any special dietary PAPERS All sessions take place in the Full papers are only available before the Symposium each requirements, please ensure they Anatomy Building Lecture Theatre. directly from the authors at their morning as well as at the breaks, are noted when registering for The programme details session discretion. Email addresses of all as indicated in the Symposium the Symposium via our online lengths with ample time for delegates are available at the end Programme. Lunch will be served registration system or please questions at the end of the session of this Symposium Programme. on both days. All those attending inform [email protected] as as well as breaks. the Symposium who are not soon as possible. The proceedings of the Symposium featured speakers are free to make are intended to be published in their own dinner plans for each the form of a Themed Issue for the day of the conference. There are British Journal of Haematology. numerous restaurants to choose We will advise all participants in from in the city centre off campus due course when the issue will be just beyond the Nassau Street/ released. Dawson Street and College Green entrances.

PHOTOCOPYING, Photocopying A listing of various Dublin internet TOURIST A tourism information centre INTERNET ACCESS, There are no photocopying café locations can be found at INFORMATION & is located very close to Trinity facilities available to use but there http://www.dublinuncovered.net/ College. It is housed in a renovated DRESS CODE & are a few retail outlets on Nassau cyber.html POST OFFICE church and is located on Suffolk CAR PARKING Street which can provide you with Street, just west of Grafton this service, for example Reads Dress Code Street, across the street from located in the Setanta Centre on The dress code for the entire O’Neill’s pub. You can also view Nassau Street (http://www.reads. Symposium including the reception tourist information at http://www. ie/photocopying.html) is smart casual. visitdublin.com/. A Post Office is located just down St Andrew Street, west of the tourist centre. Internet Access Car Parking We regret that access to the Trinity There are several public car parks WiFi system is not available to close to Trinity College. guests. There are however many WiFi hotspots in the city centre as well as internet cafés.

SOCIAL EVENTS We are arranging historical invited to a wine reception, an walking tours of campus on the opportunity to view an exhibition afternoon of Thursday 23 June, featuring some of Dr Burkitt’s 2011 beginning at 16:00. Please memorabilia in the Long Room. wear comfortable shoes and bring an umbrella. You usually do not need to worry about wearing sunscreen in Dublin. More details about the tour will be available on the day.

The tour ends at 18:00 at the Old Library where participants are

Page 12 Page 13 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: FEATURED SPEAKERS BURKITT SYMPOSIUM: FEATURED SPEAKERS

Professor GEORG W BORNKAMM 24 June 2011 Professor MITCHELL S CAIRO 24 June 2011 09:00 - 09:40 14:00 - 14:40 Institute of Clinical Molecular Biology and Tumor Generics, Maria Fareri Children’s Hospital at Westchester Medical Center, German Research Centre for Enviromental Health, Germany New York Medical College, USA

Georg W Bornkamm received his degree at the Medical School of the Ludwig-Maximilians-Universität in Munich in Mitchell S. Cairo received his M.D. from UC San Francisco, trained in pediatrics at UCLA/Harbor General Hospital, was 1970 with a thesis in Biochemistry on histones and chromatin. In 1972 he joined the lab of Nobel Laureate (2008) Harald Chief Resident in pediatrics at UCSF, and completed a fellowship in pediatric hematology/oncology at Indiana University. zur Hausen in the Department of Clinical Virology of the University of Erlangen as a post-doctoral fellow and started to He joined the hematology/oncology faculty of Children’s Hospital of Orange County (CHOC) in 1982 and established the work on the genomic structure of oncogenic herpes viruses. In 1975 he worked with Tomas Lindahl and Alice Adams BMT/Stem Cell Transplant program there in 1985. He was also the CHOC Principal Investigator for Children’s Cancer in the Department of Biochemistry and Microbiology, Tumor and Cell Biology at the Karolinska Institute in Stockholm Group, and the Principal Investigator of the Cord Blood Collection Center and Cord Blood Transplant Center under an on the episomal nature of the Epstein-Barr virus (EBV) genome in Burkitt lymphoma and Nasopharyngeal Carcinoma. NHLBI award. From December 1997 to February 2000, Dr Cairo was a member of the faculty at Georgetown University Back at the University of Erlangen he became Lecturer of Virology in 1976 (Habilitation). In 1978, he was appointed as where he was a Professor of Pediatrics, Medicine and Pathology, Chief of Pediatric Hematology/Oncology, Cellular and a Professor of Virology in the Institute of Microbiology and Hygiene at the University of Freiburg (Germany). Gene Therapy, Director of Adult and Pediatric Blood and Marrow Transplantation at the Lombardi Cancer Center, and Medical Director of the NHLBI Cord Blood Collection Center at Georgetown University Medical Center. He relocated In the early eighties, comparing the genomic structure of transforming and non-transforming EBV strains he identified to Columbia University in New York City in March 2000, where he was the Chief of the Division of Pediatric Blood and the region in the viral genome that maps for EBV´s oncogene and transcriptional master regulator EBNA2. He also Marrow Transplantation, a Professor of Pediatrics, Medicine and Pathology at Columbia University and director of the participated in the large prospective study on the role of EBV in Burkitt lymphoma in Uganda that had been organized Phase I Pediatric Cancer Therapeutics Program and Pediatric Hematology-Oncology Fellowship Training Program, and guided by Guy de Thé at the International Agency for Research on Cancer (IARC) in Lyon. From 1983 to 1989 he was the Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation. More recently, Dr Cairo has relocated Speaker and Coordinator of the Research Initiative (Sonderforschungsbereich) “Tumor Development” of the German in February, 2011 to the New York Medical College where he is the Chief of Pediatric Hematology, Oncology and Research Foundation (DFG) at the University of Freiburg. From 1989 to 2008 he has been Director of the Institute of Stem Cell Transplantation, Director of the Childhood and Adolescent Cancer and Blood Disease Center, Medical and Clinical Molecular Biology and Tumor Genetics in the Helmholtz Center Munich. In 1993/1994 he spent a sabbatical at Scientific Director of the Stem and Cellular Therapy Reengineering Laboratory and Professor of Pediatrics, Medicine, the German Cancer Center at Heidelberg. Pathology, Microbiology and Immunology and Cell Biology. Dr Cairo has over 275 peer reviewed publications and over 850 national and international presentations. He is an international leader in childhood lymphomas and leukemias, In the nineties Dr Bornkamm’s laboratory contributed significantly to our understanding of EBNA2’s mode of action stem cell transplantation, pediatric cancer developmental therapeutics, unrelated donor stem cell transplantation and as a transcription factor and developed conditional EBV-immortalized cells with reconstructed breakpoints of experimental hematopoiesis. His major research interests and expertise include blood and marrow transplantation, chromosomal translocations of Burkitt lymphoma cells and with a Tetracycline-regulatable c-Myc gene that mimic experimental and developmental immunology, molecular genetics of lymphoma, developmental therapeutics and essential features of Burkitt lymphoma cells and have become important tools to study the interplay between viral clinical leukemia and lymphoma investigation. and cellular oncogenes. The analysis of c-Myc’s immunomodulatory function in B cell lymphoma cells led him into the field of tumor immunology and initiated his present research on the generation of high-affinity T cells against Dr Cairo has focused a major part of his research in Burkitt Lymphoma. Dr Caro has led the CCG/COG Burkitt lymphoma B-cell specific differentiation antigens. He received several awards including the Gottfried-Wilhelm-Leibniz Prize of studies for the past 20 years. He was one of the three Co-Chairs and the CCG Chair of the French-American-British the German Research Foundation. Since 2008 he is running a small group as an emeritus professor at the Helmholtz (FAB) Burkitt lymphoma study that resulted in a significant reduction in both chemotherapy and radiotherapy and an Center Munich. improvement in survival in this patient population. Dr Cairo has also focused on novel immunological approaches both antibodies and cellular based therapies for Burkitt lymphoma. Lastly, Dr Cairo’s laboratory has identified a number of RECENT REVIEWS: specific genetic defects in Burkitt lymphoma and has developed targeted approaches to these genetic defects.

Bornkamm, W.W. (2009a). Epstein-Barr virus and its role in the pathogenesis of Burkitt lymphoma: an unresolved issue. Semin Cancer Biol 19, 351-365. Bornkamm, W.W. (2009a). Epstein-Barr virus and the pathogenesis of Burkitt lymphoma: more questions than answers. Int J Cancer 124, 1745-1755.

Page 14 Page 15 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: FEATURED SPEAKERS BURKITT SYMPOSIUM: FEATURED SPEAKERS

9. Compagno, M., Lim, W.K., Grunn, A., Nandula, S.V., Brahmachary, M., Shen, Q., Bertoni, F., Ponzoni, M., Professor RICCARDO DALLA-FAVERA M.D. 24 June 2011 09:40 - 10:20 Scandurra, M., Califano, A., Bhagat, G., Chadburn, A., Dalla-Favera, R. and Pasqualucci, L. Mutations of multiple Professor of Pathology and Genetics and Development, genes cause deregulation of the NF-kB pathway in diffuse large B-cell lymphoma. Nature 459:717-21, 2009. Institute for Cancer Genetics and H. Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA 10. Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L.H., Lerach, S., Ma, J., Rossi, D., Mullighan, C., Rabadan, R., Gaidano, G., Brindle, P.K., Dalla-Favera, R. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature, in press.

Riccardo Dalla-Favera, M.D. holds the Joanne and Percy Uris Chair of Clinical Medicine, he is Professor of Pathology, and Professor of Genetics & Development at the College of Physicians & Surgeons of Columbia University. He is also the Director of the Institute for Cancer Genetics, and the Director of the Herbert Irving Comprehensive Cancer Center at Columbia University. He is the Director of the Specialized Center for Research on Lymphoma at Columbia University. He is the author of 200 publications and the co-editor of the textbook “Non Hodgkin Lymphoma” (Lippincott, Williams 23 June 2011 & Wilkins publishers). Sir ANTHONY EPSTEIN MA, MD, DSc PhD, FRCPath, CBE FRS 10:45 - 11:10 Nuffield Department of Clinical Medicine, Dr Dalla-Favera has been recognized with several national awards, including the Stohlman Award from The Leukemia University of Oxford, John Radcliffe Hospital, Oxford, UK Society of America, two NIH MERIT Awards (1989, 2005), and the 2006 William Dameshek Prize for Outstanding Contribution to Hematology from The American Society of Hematology. In 2011 he has been elected to the Institute of Medicine of the National Academy of Sciences, USA. Sir Anthony Epstein was born in London 18 May 1921. He was educated at St Paul’s School, London; Trinity College, Dr Dalla-Favera has been an active researcher in the field of lymphoma research for more than 30 years. His career Cambridge; and Middlesex Hospital Medical School, London. His numerous qualifications include: MA MD (Cantab); started with his pioneering work on the cloning and chromosomal mapping of human proto-oncogenes, including DSc PhD (London); FRCPath. He has held the following appointments: Assistant Pathologist, Middlesex Hospital: c-Myc (1-2). This work established the basis for the seminal work on the involvement of c-Myc in chromosomal Reader & Hon Consultant Virologist, Middlesex Hospital Medical School; Professor of Pathology & Head of Department, translocations in Burkitt lymphoma (3-5). Then, his research has continued to yield new insights into the pathogenesis University of Bristol; Emeritus Professor at Nuffield Department of Clinical Medicine, University of Oxford & Honorary of human B cell lymphomas, and, in particular, on the identification of the genetic lesions and biological mechanisms Fellow of Wolfson College. responsible for the development of these diseases (6-10). Sir Anthony Epstein has been the recipient of a number of honours including numerous medals, honorary degrees, 1. Dalla-Favera, R., Gelmann, E.P., Martinotti, S., Franchini, G., Papas, T.S., Gallo, R.C., and Wong-Staal, F. Cloning honorary professorships and fellowships, named and leading lecturerships and holds four international prizes. He and characterization of different human sequences related to the onc-gene (v-myc) of avian myelocytomatosis was elected to the Royal Society in 1979, served on Council, as Foreign Secretary and as Vice President; was appointed virus (MC29). Proc. Nat. Acad. Sci. USA 79:6497-6501, 1982. Commander of the Order of the British Empire 1985 and Knighted in 1991.

2. Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R.C., and Croce, C.M. The human c-Myc onc-gene He has served on numerous scientific advisory committees and research boards; on Executive Council, European is located on the region of chromosome 8 which is translocated in Burkitt lymphoma cells. Science Foundation; on Executive Board, International Council of Scientific Unions; as Special Representative of the Proc. Nat. Acad. Sci. USA 79:7824-7827, 1982. Director General of UNESCO; on Advisory Group, World Bank China Key Development Project.

3. Dalla-Favera, R., Martinotti, S., Gallo, R.C., Erikson, J., and Croce, C.M. Translocation and rearrangements of the He is the author of 252 original contributions in leading international scientific journals and 5 books. He is the joint c-Myc oncogene locus in human undifferentiated B-cell lymphomas. Science 219:963-967, 1983. founder and Editor of the International Review of Experimental Pathology vols 1-26.

4. Identification of reciprocal translocation points within the c-Myc and immunoglobulin m loci in a Burkitt lymphoma. Nature 306:799-803, 1983.

5. Lombardi, L., Newcomb, E.W., and Dalla-Favera, R. Pathogenesis of Burkitt lymphoma: Expression of an activated c-Myc oncogene causes the tumorigenic conversion of EBV-infected human B-lymphoblasts. Cell 49:161-170, 1987.

6. Ye, B.H., Lista, F., LoCoco, F., Knowles, D.M., Offit, K., Chaganti, R.S.K., Dalla-Favera, R. Alterations of a Zinc-Finger Encoding Gene, BCL-6, in Diffuse Large-Cell Lymphoma. Science 262:747-750, 1993.

7. Dominguez-Sola, D., Ying, C.Y., Grandori, C., Ruggiero, L., Chen, B., Galloway, D.A., Gu, W., Gautier, J., Dalla- Favera. R. Non-transcriptional control of DNA replication by c-Myc. Nature 448(7152):445-51, 2007.

8. Pasqualucci, L., Bhagat, G., Jankovic, M., Compagno, M., Smith, P., Morse III, HC., Nussenzweig, MC., Dalla- Favera, R. AID is required for germinal center derived lymphomagenesis. Nature Genetics 40(1):108-12, 2008.

Page 16 Page 17 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: FEATURED SPEAKERS BURKITT SYMPOSIUM: FEATURED SPEAKERS

Dr JOE B. HARFORD 24 June 2011 Professor David Linch FRCP, FRCPath, FMedSci 24 June 2011 16:40 - 17:10 14:40 - 15:20 Director, Office of International Affairs 17:10 - 17:50 Professor of Haematology and Head of the Department of National Cancer Institute, National Institutes of Health Haematology, University College London (UCL) Bethesda, MD 20892, USA

David Linch is Professor of Haematology and Head of the Department of Haematology at University College London Dr Joe Harford received a Ph.D. in Biochemistry from the University of Maryland Medical School and conducted basic (UCL). He qualified in Medicine from Cambridge University and the Middlesex Hospital Medical School in 1975, and research in molecular biology and cell biology. Dr Harford has published over 120 scientific papers. Dr Harford is one then undertook SHO and Registrar positions in General Medicine before entering Haematology. He commenced his of the founding editors for Current Protocols in Cell Biology. research career at UCL as a Wellcome Trust Clinical Research Fellow and then an MRC Travelling Research Fellow to the Dana Faber Cancer Institute in Boston. In 1984 he was appointed a Senior Lecturer at the Middlesex Hospital and In 1993, Dr Harford became the chief scientist for RiboGene, Inc. (now Questcor Pharmaceuticals, Inc.), a biotechnology following the first of several London Medical School mergers he was appointed to a Chair of Haematology at UCL in company where he managed four drug discovery programs in infectious diseases. From 1996 to 1999, Dr Harford 1988. He took up the Headship of the Department of Haematology in 1992 and from 2004 to 2007 was the Chairman of served as Chairman of the Scientific Advisory Board of RiboGene, Inc, and served in a similar capacity for SynerGene the Division of Cancer Medicine at UCL. He is currently the Chairman of the CRUK Cancer Centre at UCL. Therapeutics, Inc., an early-stage biopharmaceutical company that focuses on molecular therapeutics for cancer. Dr Harford is a co-inventor on two issued U.S. patents related to drug discovery. In 1996, Dr Harford returned to the NIH His laboratory research has been in the field of myelopoiesis and myeloid leukaemias and his clinical research has where he served as Associate Director of the NCI and Chief of Staff of the Office of the Director. been focussed on the treatment of leukaemia and lymphoma with a particular focus on the development of high dose therapy strategies. He was the Goulstonian Lecturer of the Royal College of Physicians in 1988 and the recipient of the In July 2002, Dr Joe Harford was named Director of the Office of International Affairs of the National Cancer Institute. In British Society of Haematology Gold Medal in 2006. Professor Linch was the Director of the British National Lymphoma this capacity, he has responsibility for a number of bilateral and multilateral interactions between the NCI and foreign Investigation, Chairman of the UK Lymphoma Group and then the first Chairman of the NCRI Lymphoma Clinical cancer research institutions and other foreign entities. Dr Harford serves as the Chair of the Strategic Advisory Group Studies Group. He has published numerous papers on the treatment of lymphoma in adults. He is the President of of the Ireland-Northern Ireland-NCI Cancer Consortium and as NCI liaison to the Middle East Cancer Consortium, the the Lymphoma Association, a national patient advisory and support organisation. He is the Chairman of the Medical US-Japan Co-operative Cancer Research Program, the African Organization for Research and Training in Cancer, the Research Council Leukaemia Trials Steering Committee. American-Russian Cancer Alliance, and the International Network for Cancer Treatment and Research. Dr Harford has represented the United States to the Governing Council of the WHO’s International Agency for Research on Cancer Professor Linch has served on numerous advisory bodies including the Medical Advisory Panel, the Cell and Molecular and represented NIH for two years as a member of the Board of Trustees of the Human Frontier Science Program, an Panel and the International Panel of the Wellcome Trust, the Scientific Committee and the Clinical Trials Committee international non-governmental, nonprofit association devoted to the promotion of basic research. In July 2006, Dr of Leukaemia and Lymphoma Research (formerly the Leukaemia Research Fund). He currently chairs the LLR Career Harford was named as Strategic Leader for Knowledge Transfer by the Union for International Cancer Control (UICC). Development Panel. He is the immediate past President of the British Society of Haematology. In 2008, UICC altered its committee structure, and Dr Harford was named to the UICC Board of Directors (NCI Liaison), the Solidarity Fund Taskforce, the Childhood Cancer Taskforce, and the Strategic Coordinating Committee. Dr Harford has been appointed by the Irish Minister for Health and Children to the National Expert Group on Cancer Biobanking. Dr Harford also serves on the Executive Committee of the Breast Health Global Initiative that strives to develop, implement and study evidence-based, economically feasible, and culturally appropriate Guidelines for International Breast Health and Cancer Control for low and middle-income countries to improve breast health outcomes and access to breast cancer screening, detection and treatment for women.

In 2007, Dr Harford was recognized by the Arab Medical Association Against Cancer with an award, the citation of which reads “In recognition for his significant contribution to enhance the status of cancer care and cancer research in the region and for his unwavering efforts to support needed infrastructure and create opportunities in cancer education, training and capacity building to help cancer patients and their families throughout the Arab world.”

Page 18 Page 19 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: FEATURED SPEAKERS BURKITT SYMPOSIUM: FEATURED SPEAKERS

23 June 2011 Professor IAN T. MAGRATH DScMed, FRCP, FRCPath Dr JACKSON OREM MB, ChB, M.Med 23 June 2011 13:50 - 14:30 13:25 - 13:50 International Network for Cancer Treatment and Research, 24 June 2011 Director, Uganda Cancer Institute, Lecturer Makerere Brussels, Belgium 16:00 - 18:15 University School of Medicine, Kampala, Uganda 17:00 - 17:50

Ian Magrath received his qualifications in medicine from the University of London. He holds a higher doctoral degree Dr Orem served as a Fogarty Clinical Research Scholar in the Division of Hematology/Oncology (September 2002 in Medicine and is a Fellow of the Royal College of Physicians and the Royal College of Pathologists. He has a special to January 2004). Dr Orem specialized in clinical oncology at the Division of Hematology/Oncology and Case Cancer interest in the pathogenesis and treatment of non-Hodgkin’s lymphomas, stemming from early in his career when Center in line with research activities of the Developmental Therapeutics Program. He is currently involved in the he spent 2 years as Director of the Lymphoma Treatment Center in Kampala (University of Makerere), Uganda. He delivery of cancer care in resource-poor settings as well as the treatment of viral-associated malignancies including subsequently joined the National Cancer Institute (NCI), Bethesda, Maryland, and became Chief of the Lymphoma Burkitt lymphoma and the care of patients with compromised immune functions. Biology Section of the Pediatric Oncology Branch, where his work was focused on the treatment and molecular pathogenesis of B cell lymphomas, particularly Burkitt lymphoma, as well as the role of Epstein-Barr virus in the His honours include: Recipient German Academic Exchange Scholarship (1993-1996); Recipient Fogarty Foundation pathogenesis of the latter disease. During the last 35 years, he has had a particular interest in cancer control in Fellowship (2002-2004); Elected first Chair of International Burkitt lymphoma Task Force (2008); Invited speaker developing countries and has been involved in the conduct of cancer control projects, clinical trials and basic research Greater Seattle Chamber of Commerce Conference (2008); Invited education faculty American Society for Clinical in many parts of the world, including India, Pakistan, Nepal, China, Mexico, Argentina, Brazil, Turkey, Tanzania, , Oncology (2008); Annual Conference (2009); Invited speaker 42 International Society of Pediatric Oncology October Nigeria and Egypt. This led to his present position as President of the International Network for Cancer Treatment and 2010, Boston Massachusetts. Research (INCTR) in Brussels (in 2000), although he retains a position at the NCI. Dr Magrath is also adjunct Professor of Pediatrics at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He has authored SELECTED PUBLICATIONS: over 360 original articles, chapters, reviews, commentaries and editorials relating primarily to the pathogenesis and treatment of malignant lymphomas, pediatric cancers, cancer in developing countries and Epstein Barr Virus. He Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda. Phipps W, has also edited several books, including “New Directions in Cancer Treatment,” “The Non-Hodgkin’s Lymphomas” Ssewankambo F, Nguyen H, Saracino M, Wald A, Corey L, Orem J, Kambugu A, Casper C. PLoS One. 2010 Nov (now in its 3rd edition as “the Lymphoid ”), and “Gene Therapy.” He serves or has served on several 12;5(11):e13936. international committees and advisory boards for a number of organizations, including the World Health Organization, Ocular surface squamous neoplasia in patients with HIV infection in sub-Saharan Africa. the International Atomic Energy Agency (PACT), the European School of Oncology, the International Union for Cancer Control and the American Association for Cancer Research. He has won a number of awards for his work and been Nagaiah G, Stotler C, Orem J, Mwanda WO, Remick SC. Curr Opin Oncol. 2010 Sep;22(5):437-42. invited to give several special lectures at major meetings of professional societies or Universities. EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. 1. Magrath, Ian (Ed). The Lymphoid Neoplasms. Third Edition. Arnold Hodder, London, 2010. Tumwine LK, Orem J, Kerchan P, Byarugaba W, Pileri SAInfect Agent Cancer. 2010 Jun 30;5:12. 2. Magrath I. Lessons from clinical trials in African Burkitt lymphoma. Current Opinion in Oncology, 2009, 21:462–468. 3. Gascoyne RD, Magrath IT and Sehn L. Burkitt lymphoma. In Armitage J, Mauch PM, Harris NL, Coiffier B, Dalla- HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma. Yu JJ, Favera R. Non-Hodgkin lymphomas. Kluwer W. Philadelphia, pp 334-357, 2009. Fu P, Pink JJ, Dawson D, Wasman J, Orem J, Mwanda WO, Zhu H, Liang X, Guo Y, Petros WP, Mitsuyasu RT, Wabinga 4. Magrath I. B-cell Lymphoma/Burkitt lymphoma. In Pediatric Lymphomas. Weinstein H and Link M (Eds). 2006, H, Remick SC. PLoS One. 2010 May 17;5(5):e10477 141-174. Springer-Verlag, Berlin, Heidelberg. The roles of national cancer research institutions in evolving a comprehensive cancer control program in a developing country: experience from Uganda. Orem J, Wabinga H. Oncology. 2009;77(5):272-80. Epub 2009 Nov 16.

Endemic Burkitt lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Chene A, Donati D, Orem J, Mbidde ER, Kironde F, Wahlgren M, Bejarano MT. Semin Cancer Biol. 2009 Dec;19(6):411-20. Epub 2009 Nov 6.

Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, Onyango CA, Ness A, Reynolds S, Johnson JL, Subbiah V, Bako J, Wabinga H, Abdallah FK, Meyerson HJ, Whalen CC, Lederman MM, Black J, Ayers LW, Katongole-Mbidde E, Remick SC. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin’s lymphoma in East Africa. J Clin Oncol. 2009 Jul 20;27(21):3480-8. Epub 2009 May 26.

Johnston C, Orem J, Okuku F, Kalinaki M, Saracino M, Katongole-Mbidde E, Sande M, Ronald A, McAdam K, Huang ML, Drolette L, Selke S, Wald A, Corey L, Casper C. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS One. 2009;4(1):e4222. Epub 2009 Jan 20.

Orem J, Maganda A, Mbidde EK, Weiderpass E Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection. Pediatr Blood Cancer. 2008 Sep 18.

Page 20 Page 21 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: FEATURED SPEAKERS BURKITT SYMPOSIUM: FEATURED SPEAKERS

Orem J, Mbidde EK, Weiderpass E. Current investigations and treatment of Burkitt lymphoma in Africa. Trop Doct. Professor C Ross Pinkerton MB., BCh., DCH, MRCI (Paediatrics), M.D.(Hons), 24 June 2011 2008 Jan; 38(1):7-11. FRCPI, FRCCH, FRAC,P 12:20 - 13:00

Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E. Burkitt lymphoma in Africa, a review of the epidemiology Director of Children’s Cancer Services and Staff Specialist in and etiology. Afr Health Sci. 2007Sep; (3):166-75. Paediatric Oncology, Mater and Royal Children’s Hospitals, Brisbane, Professor of Oncology, School of Medicine, University Chene, A. Donati, D. Guerreiro-Cacais, A. O. Levitsky, V. Chen, Q. Falk, K. I. Orem, J. Kironde, F. Wahlgren, M. Bejarano, of Queensland, Australia M. T. A molecular link between malaria and Epstein-Barr virus reactivation PLoS Pathog 2007 Jun; 3: e80.

J.Orem, Otieno MW, Remick SC. Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol. 2006 Sep; 18(5): 479-86. Ross Pinkerton is senior staff specialist in paediatric oncology at the Royal Children’s Hospital, Brisbane and Director of the Queensland Children’s Cancer Centre. He graduated from the Queen’s University Belfast and trained in paediatrics Orem J, Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ayers L, Ghannoum M, Fu P, Feigal EG, Black J, in Dublin and London. As Leukemia Research Fund clinical fellow at the Hospital for Sick Children Great Ormond Whalen C, Lederman M, Remick SC.Capacity building for the clinical investigation of AIDS malignancy in East Africa. Street between 1982-84 he was involved in the development of treatment programmes for childhood lymphoma. In Cancer Detect Prev. 2005; 29(2): 133-145. 1985-86 he worked at the Centre Leon Berard, Lyon, investigating the role of high dose therapy and autologous stem cell rescue in lymphoma and the use of chemotherapy purging of reinfused marrow. He returned to the Royal Marsden J.Orem, Otieno Mwanda W, Remick SC. AIDS-associated cancer in developing nations. Current Opinion in oncology Hospital , London and was appointed consultant paediatric oncologist in 1990 and was involved in the development of 2004,16:468-476. the children’s cancer service and the research facility at the Institute of Cancer Research. He was appointed Cancer Research UK professor of paediatric oncology at the Institute in 1995 and chaired the United J. Orem, Pingfu Fu, A Ness, Otieno Mwanda W. Remick SC. Oral Combination Kingdom Children’s Cancer Study Group (UKCCSG) from 1999-2002. As chair of the UKCCSG NHL working group he chemotherapy in the treatment of AIDS-Associated Hodgkin’s Disease. East Afr. Med. J. 2005; 82(Suppl) 9 2005. developed close links with the French paediatric oncology group leading to collaborative studies in Burkitt lymphoma and the eventual French American British FAB LMB trials.

His research interests have focussed on the development of novel chemotherapy strategies and the mechanism of drug resistance in children’s cancers. He has played an active role in the development and execution of national and international clinical trials in a range of paediatric tumour types and chaired the UKCCSG New Agents group.

He is the author of over 250 peer reviewed papers including a number on the management of childhood lymphoma. He editor of textbooks including ‘Evidence Based Paediatric Oncology’ and ‘Paediatric Oncology.’

In 2003 he moved to Australia as director of cancer services at the Mater Hospital Brisbane and Professor of Oncology at the University of Queensland and is currently clinical lead of the statewide Paediatric Haematology Oncology Network.

Page 22 Page 23 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: FEATURED SPEAKERS BURKITT SYMPOSIUM: FEATURED SPEAKERS

Professor JOHN T SANDLUND, JR M.D. 24 June 2011 Professor STEPHEN SCHUSTER M.D. 24 June 2011 11:40 - 12:20 16:00 - 16:40 St. Jude Children’s Research Hospital, Memphis, Associate Professor Stephen Schuster Tennessee, USA University Of Pennsylvania Medical School

Dr John T. Sandlund, Jr., M.D. completed his undergraduate training at the Ohio State University. He also received his Stephen J. Schuster is the Robert and Margarita Louis-Dreyfus Associate Professor of Chronic Lymphocytic Leukemia medical degree from the Ohio State University College of Medicine and graduated a member of A.O.A. He subsequently and Lymphoma, Associate Professor of Medicine, and Associate Professor of Radiation Oncology at the University of completed his pediatric internship and residency training at the Columbus Children’s Hospital in Columbus, Ohio. Pennsylvania School of Medicine in Philadelphia, Pennsylvania. He also serves as Director of the Lymphoma Program Dr Sandlund then received his pediatric hematology-oncology fellowship training along with an additional year of and Director of Lymphoma Translational Research at the Abramson Cancer Center of the University of Pennsylvania. training as a biotechnology fellow at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland. Dr Ian Magrath was his mentor at the NCI and provided key leadership in his career development which focused on After graduating from Jefferson Medical College and completing a residency in Internal Medicine at Pennsylvania the pediatric non-Hodgkin lymphomas (NHL) - specifically Burkitt lymphoma. In 1987, Dr Sandlund was recruited to Hospital, Dr Schuster went on to clinical and research fellowships at the Cardeza Foundation for Haematologic the St Jude Children’s Research Hospital in Memphis, TN, as an assistant member with a joint appointment at the Research. In 1989, he became a member of the Cardeza Foundation and joined the faculty at Jefferson Medical College. University of Tennessee, College of Medicine as an assistant professor. He is currently full member at St Jude and He joined the Haematologic Malignancy Department at the University of Pennsylvania in 1998. Since that time, his professor of pediatrics at the University of Tennessee, College of Medicine. Dr Sandlund’s research at St Jude has research has focused on the development and application of novel immunotherapies for non-Hodgkin lymphomas and focused on pediatric NHL and acute lymphoblastic leukemia (ALL). He has been the principle investigator (PI) for chronic lymphocytic leukemia, including use of autologous tumor-derived vaccines, autologous co-stimulated T cells a number of frontline clinical trials at St Jude and more recently the PI of a phase I/II pilot study in the Children’s for immune reconstitution after chemotherapy, radioimmunotherapy, and monoclonal antibody therapy. Oncology Group, where he is also a member of the NHL steering committee. He is currently the clinical director of the leukemia lymphoma division and oversees NHL research initiatives at St Jude. He has authored or co-authored Dr Schuster is a recipient of the deVilliers Society Award for outstanding support to the cause of fighting blood-related over 150 publications. His current research initiatives include: Burkitt lymphoma: prospective study of biologic cancers and improving the quality of life for patients and their families, the Research Recognition Award, and the Hope features and late effects of therapy; lymphoblastic lymphoma: development of MDD/MRD risk based clinical trial; and Award for Medical Achievement from the Leukemia and Lymphoma Society. He has received numerous awards for anaplastic large cell lymphoma: study of targeted therapy using immunotherapeutic agents. He also participates in outstanding teaching and research from both Jefferson Medical College and the University of Pennsylvania. the international outreach program at St Jude.

Dr TRISH SCANLAN M.D. 23 June 2011 13:00 - 13:25 The Ocean Road Cancer Institute, Tanzania

Dr Trish Scanlan is a graduate of University College Dublin and spent most of her Irish career at Our Lady’s Children’s Hospital Crumlin in Dublin. In 2007 she relocated to Dar es Salaam in Tanzania as the INCTR East Africa Programme Co-ordinator and to run the National Children’s Oncology Centre in the Ocean Road Cancer Institute. The service has recently relocated to the University Hospital. She is still in Tanzania and admits, she is still mostly sane!

Page 24 Page 25 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: FEATURED SPEAKERS BURKITT SYMPOSIUM: FEATURED SPEAKERS

Professor OWEN PATRICK SMITH MA, MB, BA Mod.(Biochem.), FRCPCH, 23 June 2011 Professor LOUIS M STAUDT M.D. Ph.D. 24 June 2011 FRCPI, FFpathRCPI, FRCPEdin, FRCPLon, FRCP Glasg, FRCPath, DHMSA, Hon FTCD 09:30 - 10:00 10:20 - 11:00 10:00 - 10:20 Chief, Lymphoid Malignancies Section, Deputy Chief, Professor of Haematology, 10:00 - 12:05 Metabolism Branch, Centre for Cancer Research, The University of Dublin, Trinity College Dublin, Ireland 13:00 - 14:50 National Cancer Institute, Maryland, USA Consultant Paediatric Haematologist, 24 June 2011 Our Lady’s Children’s Hospital, Crumlin, Dublin 12 17:10 - 17:50 17:50 - 18:05 Dr Staudt received his B.A. from Harvard College in 1976, graduating Cum Laude in Biochemistry. He was awarded a Medical Scientist Training Program fellowship at the University of Pennsylvania School of Medicine and received his M.D. and Ph.D. degrees in 1982. His Ph.D. thesis in the field of immunology, performed in the laboratory of Walter Gerhard, Professor Smith is a Consultant Paediatric Haematologist at Our Lady’s Children’s Hospital Dublin, and is Professor of revealed somatic hypermutation as a mechanism of rapid antibody diversification during normal immune responses. Haematology at the University of Dublin, Trinity College Dublin. His active research areas of interest include: childhood Following Internal Medicine training, he joined Nobel Laureate David Baltimore’s laboratory at the Whitehead Institute and adolescent leukaemias & lymphomas, bone marrow failure syndromes, angiogenesis and haematological as a Jane Coffin Childs Fellow. There he cloned and characterized the first tissue specific transcription factor, Oct-2. malignancies, the molecular and cellular basis of the inflammatory - coagulation interface in human disease. The He established his laboratory in the Metabolism Branch, National Cancer Institute, in 1988, and currently studies the co-author of more than 300 research original articles, letters, books, book chapters and papers, Professor Smith is molecular basis of human lymphoid malignancies. Dr Staudt is currently Deputy Chief of the Metabolism Branch and a Fellow of the Royal College of Pathologists, the Royal College of Physicians of Dublin, London, Glasgow, Edinburgh he also co-directs the Lymphoma/Leukemia Molecular Profiling Project (LLMPP), a multi-institutional consortium and the Royal College of Paediatrics and Child Health. He is a member of numerous associations and societies, that aims to develop a new molecular framework for the diagnosis of all lymphoid malignancies. Dr Staudt serves including; the Medical Research Council Childhood Leukaemia Working Party, the International Berlin Frankfurt on the Editorial Boards of Cancer Cell, The Journal of Experimental Medicine and Genome Biology. He has received Munster Study Group for Childhood Leukaemia, the Haemophilia Centre Directors’ Organisation, numerous awards for his research, including the 2009 Dameshek Prize from the American Society of Hematology for the European Paediatric Network for Haemophilia Management, the United Kingdom Children’s Cancer Group, the outstanding contribution in hematology. Paediatric Haematology Forum of the British Society of Haematology, and the European Paediatric Network for Severe Congenital Neutropenia. He was awarded the Graves Medal by the Royal Academy of Medicine and Health Dr Staudt’s laboratory initiated the use of genomic-scale gene expression profiling to define the molecular basis of Research Board in 2001 for his research into the pathobiology and novel therapeutic strategies in severe sepsis that therapeutic response and survival in lymphoid malignancies. This effort revealed that the most common type of non- had received international acclaim. In 2006, Professor Smith was awarded the St Luke’s Medal by the Royal Academy Hodgkin’s lymphoma, diffuse large B-cell lymphoma, is actually comprised of three distinct diseases with different of Medicine and St Luke’s Hospital for his work on improving outcomes in adolescent cancers with specific reference responses to chemotherapy. With respect to Burkitt lymphoma, Dr Staudt’s laboratory created a gene expression- to the haematological malignancies. He was admitted to Honorary Fellowship of Trinity College Dublin (the oldest and based diagnostic method that distinguished this entity from diffuse large B cell lymphoma (Dave et al. NEJM 2006 most valued tradition of the University) in 2009. 354:2431). This molecular diagnosis was based on 4 gene expression signatures, with Burkitt lymphomas having high expression of c-Myc and its target genes, and a subset of germinal center B cell-restricted genes, and low expression of NF-kB target genes and MHC class-I genes. Importantly, Dr Staudt’s gene expression-based diagnostic method identified a substantial number of cases as ‘molecular’ Burkitt lymphoma that appear to be misdiagnosed as diffuse large B cell lymphoma by current diagnostic methods. This distinction is critically important because Burkitt lymphoma and diffuse large B cell lymphoma require different chemotherapeutic regimens to be cured.

Page 26 Page 27 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: FEATURED SPEAKERS BURKITT SYMPOSIUM: FEATURED SPEAKERS

Professor DENNIS HOWARD WRIGHT 23 June 2011 Professor JOHN L. ZIEGLER M.D., M.Sc. 23 June 2011 10:20 - 10:45 11:10 - 11:45 Former Histopathologist at Makerere Medical School, Uganda Professor at University of California-San Francisco, 24 June 2011 San Francisco, California, USA 17:10 - 17:50

I was educated at the City of Norwich boys grammar school before going to the University of Bristol to study Medicine. John L. Ziegler, M.D., M.Sc. was educated at Amherst College where he received a bachelors degree in English I was awarded an intercalated BSc in Physiology in 1953 and qualified MB, ChB (Hons) in 1956. After internships Literature in 1960. After earning an M.D. at Cornell University Medical College he undertook medical residency training in paediatrics and surgery I trained in Clinical Pathology at Bristol Royal Infirmary. In 1960 the Recruitment Board at Bellevue Hospital and Memorial-Sloan-Kettering Hospitals in New York City. Joining the National Cancer Institute in allowed me to take up the post of Lecturer in Pathology at Makerere College, Uganda, instead of doing two years 1966, he embarked on a long career in cancer research. He was the founding Director of the Uganda Cancer Institute national service. Soon after my arrival in Uganda Dr Greg O’Conor, who collaborated with Denis Burkitt on two early in 1967 and after five years of research, teaching and clinical work in Uganda he was honored by the Albert and Mary publications, left Uganda and I took over as “Mr Burkitt’s pathologist”. He called me to theatre when he operated on Lasker Award in 1972 for improving the cure rate of Burkitt lymphoma, a common childhood malignancy. During the lymphoma cases so that I could collect fresh tissue, blood and bone marrow. In return I was able to give him a rapid 1970s he was Chief of Pediatric Oncology and later Director of Clinical Oncology at the National Cancer Institute. cytological diagnosis and on many occasions administer the first dose of cyclophosphamide while I had a needle in a vein for blood taking. Denis and I collaborated together on a number of published studies on Burkitt lymphoma. In 1981 Dr Ziegler joined the University of California San Francisco as Professor of Medicine in residence and Chief of Together, we edited a book on Burkitt lymphoma in 1970. We travelled together to a number of meetings in Europe Staff for Education at the VA Hospital. Here, he participated in the early research on the AIDS epidemic, being the first and America. At a Symposium on lymphoreticular tumours in Africa held in Paris in 1963 I proposed that the tumour, to show an association with malignant lymphoma and Kaposi’s sarcoma — tumors he encountered earlier in Uganda. then often given the unsatisfactory name “African lymphoma” or “childhood lymphoma” should be called Burkitt Ziegler was also instrumental in the discovery of viral causes of Burkitt lymphoma and Kaposi’s sarcoma. lymphoma. (This was accepted except that some of the big guns insisted that we use the term Burkitt’s tumour since they were not sure that it was a lymphoma). In 1985 Prof Ziegler became the Founding Director of the UCSF AIDS Clinical Research Center and made many scientific contributions in the area of HIV-associated malignancies, both in the USA and in Uganda. He was invited to I was awarded an MD for my thesis ‘Malignant lymphomas in Uganda’ in 1965. Denis left Uganda in 1966 and I followed consult with the World Health Organization in 1994-96 and in 1997 earned a masters degree in epidemiology at the in 1968 to take up the post of Senior Lecturer and later Reader in Pathology at the University of Birmingham. In 1971 I London School of Hygiene and Tropical Medicine. was appointed Professor of Pathology at the newly formed Medical School at the University of Southampton. From 1998 to 2007, Ziegler has directed the Cancer Risk Program at the UCSF Comprehensive Cancer Center, now one of the leading genetic counseling and testing centers for hereditary cancer in northern California. Starting in 2007, he was named Director of the Global Health Sciences Graduate Program, crafting a curriculum for a masters degree in global health sciences at UCSF. This Program, the first of its kind in the US, graduated an inaugural class of 7 students in 2009 and enrolment has quickly reached 30 students annually. Ziegler has authored over 240 scientific articles, chapters and reviews and is the recipient of numerous awards that honor his work in cancer and global health.

Ziegler has had a career-long interest in medical education and, as a recipient of two Fulbright awards, has taught clinical medicine for eight years at Makerere University in Kampala, Uganda. He has also taught as visiting professor at Cambridge and Oxford Universities, Cairo University, and at the London School of Hygiene and Tropical Medicine.

Page 28 Page 29 23 - 24 June 2011 23 - 24 June 2011 BURKITT SYMPOSIUM: NOTES BURKITT SYMPOSIUM: NOTES

NOTES NOTES

Page 30 Page 31 23 - 24 June 2011 BURKITT SYMPOSIUM: NOTES

NOTES

Page 32